التداخل بين سيناكالسيت وفلوفوكسامين

Dose adjustments may be required for concomitant medications that are predominantly metabolized by CYP2D6 (e.g., desipramine, metoprolol, and carvedilol) and particularly those with a narrow therapeutic index (e.g., flecainide and most tricyclic antidepressants) [see Clinical Pharmacology ( 12.3 )] .

In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.